IVACAFTOR 188 MG / LUMACAFTOR 150 MG ORAL GRANULES [ORKAMBI]

Side Effects & Adverse Event Reports


View Chart Data

16.6K

Adverse Events

33.6K

Side Effects

2012

Data Starting In

SymPedia Mobile App

Get our Mobile App for easy access to the latest reports on IVACAFTOR 188 MG / LUMACAFTOR 150 MG ORAL GRANULES [ORKAMBI].

Understanding the potential Side Effects and Adverse Events of IVACAFTOR 188 MG / LUMACAFTOR 150 MG ORAL GRANULES [ORKAMBI] is essential for making informed health decisions. Our application provides in-depth reports based on real-world data, helping you explore how IVACAFTOR 188 MG / LUMACAFTOR 150 MG ORAL GRANULES [ORKAMBI] may affect your health.

View reports containing much more information including:

  • Age group - See how different age ranges experience side effects and adverse reactions.
  • Year - Track trends over time to understand changes in reported issues.
  • Biological sex - Compare how reports vary between men and women.
  • Weight - Examine the impact of body weight on side effects and adverse events.
Download Now

Frequently Asked Questions

Some questions about IVACAFTOR 188 MG / LUMACAFTOR 150 MG ORAL GRANULES [ORKAMBI] are asked frequently. We've answered the most frequent of those questions below

  • How many adverse events have been reported for IVACAFTOR 188 MG / LUMACAFTOR 150 MG ORAL GRANULES [ORKAMBI]?

    SymPedia shows IVACAFTOR 188 MG / LUMACAFTOR 150 MG ORAL GRANULES [ORKAMBI] adverse event reports for 16,568.

  • How many side effects have been reported for IVACAFTOR 188 MG / LUMACAFTOR 150 MG ORAL GRANULES [ORKAMBI]?

    SymPedia shows IVACAFTOR 188 MG / LUMACAFTOR 150 MG ORAL GRANULES [ORKAMBI] side effect reports for 33,563.

  • What year does the IVACAFTOR 188 MG / LUMACAFTOR 150 MG ORAL GRANULES [ORKAMBI] reporting data start?

    SymPedia reporting data on this page starts in 2012.

  • What years are included in the yearly chart for IVACAFTOR 188 MG / LUMACAFTOR 150 MG ORAL GRANULES [ORKAMBI]?

    SymPedia yearly chart data on this page covers 2012 to 2025.